Yep - eye watering isn't it. The SP really has to be the most...

Yep - eye watering isn't it. The SP really has to be the most unloved on the ASX. Niche retail investors, who favour biotechs and get the tech, the progress, the potential, the deep story so far have run out of steam to move this with any conviction. Any new retail investors are most likely not biotech or industry specialists, the story so far does not excite them as its not what they do their DD on. Now, to attact the retail masses (that are not already deeply invested) the story needs to change heavily from how good the tech is, to the commercialisation and $$$. If this is compelling enough, the masses will come as its what they understand and focus on when making investment decisions...Pivot the story, its time - move towards the path to revenue and all that sits between it...entice the masses by talking in the small cap investment thesis they understand...